JP2017522877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522877A5 JP2017522877A5 JP2017503089A JP2017503089A JP2017522877A5 JP 2017522877 A5 JP2017522877 A5 JP 2017522877A5 JP 2017503089 A JP2017503089 A JP 2017503089A JP 2017503089 A JP2017503089 A JP 2017503089A JP 2017522877 A5 JP2017522877 A5 JP 2017522877A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- fhbp
- variant
- substitution
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 94
- 101710186862 Factor H binding protein Proteins 0.000 claims description 93
- 238000006467 substitution reaction Methods 0.000 claims description 84
- 235000001014 amino acid Nutrition 0.000 claims description 74
- 229940024606 amino acid Drugs 0.000 claims description 17
- 230000005875 antibody response Effects 0.000 claims description 11
- 230000002163 immunogen Effects 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 102000045512 human CFH Human genes 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 241000588650 Neisseria meningitidis Species 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 102200128616 rs121908751 Human genes 0.000 claims description 4
- 102220466919 Runt-related transcription factor 1_R80A_mutation Human genes 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 102220534532 Protein quaking_Q38K_mutation Human genes 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical group O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 102220481542 eIF5-mimic protein 2_R41A_mutation Human genes 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 2
- 150000002333 glycines Chemical class 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102220279362 rs1554893806 Human genes 0.000 claims description 2
- 102220056952 rs730880947 Human genes 0.000 claims description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 125000002987 valine group Chemical class [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028123P | 2014-07-23 | 2014-07-23 | |
| US62/028,123 | 2014-07-23 | ||
| PCT/US2015/041616 WO2016014719A1 (en) | 2014-07-23 | 2015-07-22 | Factor h binding protein variants and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158515A Division JP7221917B2 (ja) | 2014-07-23 | 2020-09-23 | Ｈ因子結合タンパク質変異体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522877A JP2017522877A (ja) | 2017-08-17 |
| JP2017522877A5 true JP2017522877A5 (cg-RX-API-DMAC10.html) | 2018-08-30 |
| JP6796057B2 JP6796057B2 (ja) | 2020-12-02 |
Family
ID=55163727
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503089A Active JP6796057B2 (ja) | 2014-07-23 | 2015-07-22 | Ｈ因子結合タンパク質変異体及びその使用方法 |
| JP2020158515A Active JP7221917B2 (ja) | 2014-07-23 | 2020-09-23 | Ｈ因子結合タンパク質変異体及びその使用方法 |
| JP2022180069A Active JP7719046B2 (ja) | 2014-07-23 | 2022-11-10 | Ｈ因子結合タンパク質変異体及びその使用方法 |
| JP2025071948A Pending JP2025108722A (ja) | 2014-07-23 | 2025-04-24 | Ｈ因子結合タンパク質変異体及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158515A Active JP7221917B2 (ja) | 2014-07-23 | 2020-09-23 | Ｈ因子結合タンパク質変異体及びその使用方法 |
| JP2022180069A Active JP7719046B2 (ja) | 2014-07-23 | 2022-11-10 | Ｈ因子結合タンパク質変異体及びその使用方法 |
| JP2025071948A Pending JP2025108722A (ja) | 2014-07-23 | 2025-04-24 | Ｈ因子結合タンパク質変異体及びその使用方法 |
Country Status (15)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802933T4 (tr) | 2010-03-30 | 2018-03-21 | Childrens Hospital & Res Center At Oakland | Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi. |
| BR112017001417B1 (pt) | 2014-07-23 | 2023-11-07 | Children's Hospital & Research Center At Oakland | Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada |
| GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
| KR101855133B1 (ko) | 2016-11-16 | 2018-05-08 | 주식회사 케이엠더블유 | 적층구조의 mimo 안테나 어셈블리 |
| WO2018093176A2 (ko) | 2016-11-16 | 2018-05-24 | 주식회사 케이엠더블유 | 적층구조의 mimo 안테나 어셈블리 |
| KR102822764B1 (ko) * | 2017-12-04 | 2025-06-19 | 인트라백 비.브이. | 외막 소포의 생성을 위한 개선된 방법 |
| EP3607967A1 (en) * | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| GB202016604D0 (en) | 2020-10-20 | 2020-12-02 | Univ Of Oxford | Compositions and methods for inducing an immune response |
| TW202245836A (zh) | 2021-02-19 | 2022-12-01 | 美商賽諾菲巴斯德公司 | 重組ｂ型腦膜炎球菌疫苗 |
| TW202423477A (zh) | 2022-08-03 | 2024-06-16 | 美商賽諾菲巴斯德公司 | 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物 |
| WO2026072910A1 (en) | 2024-09-27 | 2026-04-02 | Sanofi Pasteur Inc. | Anti-meningococcal antibodies for in vitro immunoassay |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| US20070026021A1 (en) | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| MX343752B (es) | 1998-05-01 | 2016-11-22 | Novartis Vaccines & Diagnostics Inc | Antigenos de neisseria meningitidis y composiciones que los contienen. |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| ES2284287T3 (es) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
| CA2366152A1 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Streptococcus pneumoniae vaccine |
| DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| IL148671A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| HK1049106A1 (zh) | 1999-09-24 | 2003-05-02 | Smithkline Beecham Biologicals S.A. | 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途 |
| WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
| AU2013206190A1 (en) | 1999-11-29 | 2013-06-27 | Novartis Vaccines And Diagnostics S.R.L. | Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen |
| ES2588917T3 (es) | 2000-01-17 | 2016-11-07 | Glaxosmithkline Biologicals Sa | Vacuna de VME suplementada contra meningococo |
| PT2270030E (pt) | 2000-02-28 | 2012-07-24 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| US6839862B2 (en) | 2001-05-31 | 2005-01-04 | Koninklijke Philips Electronics N.V. | Parallel data communication having skew intolerant data groups |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| EP2351579B1 (en) | 2002-10-11 | 2016-09-21 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| WO2004074433A2 (en) | 2003-01-30 | 2004-09-02 | Yale University | Rag polypeptides, nucleic acids, and their use |
| US7628995B2 (en) * | 2003-12-23 | 2009-12-08 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicles and uses thereof |
| GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| CN101107007B (zh) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗 |
| ZA200707420B (en) | 2005-02-14 | 2009-04-29 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| WO2009038889A1 (en) | 2007-08-02 | 2009-03-26 | Children's Hospital And Research Center At Oakland | Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| AU2009215364B2 (en) * | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
| AU2009223613B2 (en) * | 2008-03-10 | 2014-09-25 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
| US8476032B2 (en) | 2008-08-27 | 2013-07-02 | Children's Hospital & Research Center Oakland | Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis |
| WO2010028096A2 (en) | 2008-09-03 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
| GB0819633D0 (en) * | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
| CN104548082A (zh) | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
| US9266942B2 (en) | 2009-04-30 | 2016-02-23 | Children's Hospital & Research Center Oakland | Chimeric factor H binding proteins (fHbp) and methods of use |
| CA2779816A1 (en) * | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| TR201802933T4 (tr) * | 2010-03-30 | 2018-03-21 | Childrens Hospital & Res Center At Oakland | Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi. |
| KR101584871B1 (ko) * | 2010-09-10 | 2016-01-22 | 와이어쓰 엘엘씨 | 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체 |
| CN102028941B (zh) | 2011-02-11 | 2013-02-13 | 中国医学科学院医学生物学研究所 | 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法 |
| EP2729167B1 (en) | 2011-07-07 | 2018-03-14 | De Staat der Nederlanden, vert. door de Minister van VWS | A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium |
| WO2013078223A1 (en) | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| CA2865745C (en) * | 2012-03-09 | 2018-01-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| GB201215005D0 (en) | 2012-08-23 | 2012-10-10 | Isis Innovation | Stabilised meningitis vaccine |
| WO2015017817A1 (en) * | 2013-08-02 | 2015-02-05 | Children's Hospital & Research Center Oakland | Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof |
| CN106661092B (zh) | 2014-02-28 | 2021-07-06 | 葛兰素史密丝克莱恩生物有限公司 | 修饰的脑膜炎球菌fHbp多肽 |
| KR20150128099A (ko) | 2014-05-08 | 2015-11-18 | (주)엘지하우시스 | Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법 |
| CN107349423B (zh) * | 2014-06-24 | 2021-03-19 | 上海生物制品研究所有限责任公司 | 一种脑膜炎球菌抗原组合及其应用 |
| MX2017000776A (es) * | 2014-07-17 | 2017-05-04 | Glaxosmithkline Biologicals Sa | Polipeptidos fhbp meningococicos modificados. |
| BR112017001417B1 (pt) | 2014-07-23 | 2023-11-07 | Children's Hospital & Research Center At Oakland | Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada |
| EP3607967A1 (en) * | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
-
2015
- 2015-07-22 BR BR112017001417-3A patent/BR112017001417B1/pt active IP Right Grant
- 2015-07-22 RU RU2017104742A patent/RU2714248C2/ru active
- 2015-07-22 EP EP22174947.6A patent/EP4074726A3/en active Pending
- 2015-07-22 WO PCT/US2015/041616 patent/WO2016014719A1/en not_active Ceased
- 2015-07-22 CR CR20170020A patent/CR20170020A/es unknown
- 2015-07-22 CN CN202110192031.1A patent/CN112851768A/zh active Pending
- 2015-07-22 ES ES15824545T patent/ES2922554T3/es active Active
- 2015-07-22 MX MX2017001038A patent/MX382409B/es unknown
- 2015-07-22 KR KR1020177004378A patent/KR102752259B1/ko active Active
- 2015-07-22 NZ NZ766005A patent/NZ766005A/en unknown
- 2015-07-22 EP EP15824545.6A patent/EP3172224B1/en active Active
- 2015-07-22 CA CA3212723A patent/CA3212723A1/en active Pending
- 2015-07-22 JP JP2017503089A patent/JP6796057B2/ja active Active
- 2015-07-22 CA CA2955802A patent/CA2955802C/en active Active
- 2015-07-22 CN CN201580043542.XA patent/CN106715464B/zh active Active
- 2015-07-22 US US15/327,346 patent/US10266572B2/en active Active
- 2015-07-22 NZ NZ729206A patent/NZ729206A/en unknown
- 2015-07-22 AU AU2015292615A patent/AU2015292615B2/en active Active
- 2015-07-22 CN CN202411821930.3A patent/CN119613509A/zh active Pending
- 2015-07-22 KR KR1020237036853A patent/KR102761870B1/ko active Active
-
2017
- 2017-01-23 MX MX2021005373A patent/MX2021005373A/es unknown
- 2017-01-23 CO CONC2017/0000558A patent/CO2017000558A2/es unknown
- 2017-01-23 MX MX2023000204A patent/MX2023000204A/es unknown
-
2019
- 2019-02-28 US US16/288,760 patent/US10487122B2/en active Active
- 2019-10-11 US US16/600,259 patent/US10836799B2/en active Active
- 2019-10-11 US US16/600,282 patent/US10995122B2/en active Active
- 2019-11-14 AU AU2019264600A patent/AU2019264600B2/en active Active
-
2020
- 2020-09-23 JP JP2020158515A patent/JP7221917B2/ja active Active
- 2020-10-07 US US17/065,386 patent/US11834476B2/en active Active
-
2021
- 2021-04-02 US US17/221,646 patent/US11673920B2/en active Active
- 2021-06-10 AU AU2021203828A patent/AU2021203828B2/en active Active
-
2022
- 2022-11-10 JP JP2022180069A patent/JP7719046B2/ja active Active
-
2023
- 2023-05-12 US US18/316,594 patent/US12129282B2/en active Active
- 2023-07-07 AU AU2023204391A patent/AU2023204391B2/en active Active
- 2023-10-24 US US18/493,141 patent/US12269849B2/en active Active
-
2024
- 2024-09-19 US US18/890,476 patent/US20250136648A1/en active Pending
-
2025
- 2025-01-14 US US19/020,854 patent/US20250154206A1/en active Pending
- 2025-04-22 AU AU2025202774A patent/AU2025202774A1/en active Pending
- 2025-04-24 JP JP2025071948A patent/JP2025108722A/ja active Pending